Novo may raise sales target of obesity drug after stellar demand

Novo Nordisk A/S is considering raising the sales guidance for its obesity drugs after a strong introduction for its new medication called Wegovy, chief executive officer (CEO) Lars Fruergaard Jorgensen said in an interview.

from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/3wkUtJ7